# MYRIAD GENETICS INC (MYGN) Informational only - not investment advice. CIK: 0000899923 SIC: 2835 In Vitro & In Vivo Diagnostic Substances SIC breadcrumb: [Manufacturing](/division/D/) > [Chemicals And Allied Products](/major-group/28/) > [SIC 2835 In Vitro & In Vivo Diagnostic Substances](/industry/2835/) Latest 10-K filed: 2026-02-24 SEC page: https://www.sec.gov/edgar/browse/?CIK=899923 Filing source: https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/mygn-20251231.htm ## At a glance FY2025 · period end 2025-12-31 · filed 2026-02-24 · accession 0000899923-26-000018 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000899923.json | Metric | Value | FY | Provenance | | --- | ---: | ---: | --- | | Revenue | 824,500,000 USD | 2025 | verified | | Net income | -365,900,000 USD | 2025 | verified | | Assets | 706,600,000 USD | 2025 | verified | | Free cash flow | -13,800,000 USD | 2025 | computed | | Net margin | -44.38% | 2025 | computed | | Operating margin | -46.96% | 2025 | computed | | Revenue YoY | -1.56% | 2025 | computed | | ROE | -99.43% | 2025 | computed | Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity. No market price, no rating, no forecast on this site. Not investment advice. ### Peer percentile fingerprint | Ratio | MYGN | Peer median | Percentile | N | | --- | ---: | ---: | ---: | ---: | | Revenue growth | -1.6% | -0.5% | 43 | 8 | | FCF margin | -1.7% | -2.4% | 57 | 8 | | ROE | -99.4% | -37.1% | 0 | 8 | | ROA | -51.8% | -18.1% | 0 | 8 | | Liabilities / equity | 0.92 | 0.76 | 57 | 8 | | Current ratio | 2.49 | 3.26 | 29 | 8 | Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 2835 In Vitro & In Vivo Diagnostic Substances, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking. ## Selected Fundamentals | Metric | Value | Unit | FY | Filed | | --- | ---: | --- | ---: | --- | | Revenue | 824500000 | USD | 2025 | 2026-02-24 | | Net income | -365900000 | USD | 2025 | 2026-02-24 | | Assets | 706600000 | USD | 2025 | 2026-02-24 | ## Financials Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-24. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000899923.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts. | Metric | 2009 | 2010 | 2011 | 2012 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | | | | | 740,500,000 | 728,700,000 | 743,700,000 | 851,100,000 | 638,600,000 | 690,600,000 | 678,400,000 | 753,200,000 | 837,600,000 | 824,500,000 | | Net income | | | | | 117,200,000 | 17,400,000 | 133,300,000 | 4,600,000 | -199,500,000 | -27,200,000 | -112,000,000 | -263,300,000 | -127,300,000 | -365,900,000 | | Operating income | | | | | 153,400,000 | 44,000,000 | 121,900,000 | 7,600,000 | -231,700,000 | -190,500,000 | -140,600,000 | -257,400,000 | -123,500,000 | -387,200,000 | | Gross profit | | | | | | | | | | | 476,400,000 | 517,000,000 | 585,400,000 | 576,600,000 | | Diluted EPS | | | | | 1.60 | 0.25 | 1.85 | 0.06 | -2.69 | -0.35 | -1.39 | -3.18 | -1.41 | -3.95 | | Operating cash flow | | | | | 166,300,000 | 106,200,000 | 115,900,000 | 83,700,000 | 60,700,000 | 18,600,000 | -106,300,000 | -110,900,000 | -8,700,000 | 1,800,000 | | Capital expenditures | 2,100,000 | 100,000 | 100,000 | 100,000 | | | | | | 18,000,000 | 45,300,000 | 63,200,000 | 19,000,000 | 15,600,000 | | Assets | | | | | 880,500,000 | 1,208,900,000 | 1,175,300,000 | 1,562,700,000 | 1,418,800,000 | 1,320,700,000 | 1,198,700,000 | 1,146,500,000 | 1,027,600,000 | 706,600,000 | | Liabilities | | | | | 132,400,000 | 440,900,000 | 209,200,000 | 473,800,000 | 537,800,000 | 352,900,000 | 312,900,000 | 363,300,000 | 326,500,000 | 338,600,000 | | Stockholders' equity | | | | | 739,600,000 | 768,400,000 | 966,100,000 | 1,088,900,000 | 881,000,000 | 967,800,000 | 885,800,000 | 783,200,000 | 701,100,000 | 368,000,000 | | Cash and cash equivalents | | | | | 68,500,000 | 102,400,000 | 110,900,000 | 93,200,000 | 117,000,000 | 257,400,000 | 56,900,000 | 132,100,000 | 102,400,000 | 149,600,000 | | Free cash flow | | | | | | | | | | 600,000 | -151,600,000 | -174,100,000 | -27,700,000 | -13,800,000 | ### Ratios ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported. | Metric | 2009 | 2010 | 2011 | 2012 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Net margin | | | | | 15.83% | 2.39% | 17.92% | 0.54% | -31.24% | -3.94% | -16.51% | -34.96% | -15.20% | -44.38% | | Operating margin | | | | | 20.72% | 6.04% | 16.39% | 0.89% | -36.28% | -27.58% | -20.73% | -34.17% | -14.74% | -46.96% | | Return on equity | | | | | 15.85% | 2.26% | 13.80% | 0.42% | -22.64% | -2.81% | -12.64% | -33.62% | -18.16% | -99.43% | | Return on assets | | | | | 13.31% | 1.44% | 11.34% | 0.29% | -14.06% | -2.06% | -9.34% | -22.97% | -12.39% | -51.78% | | Liabilities / equity | | | | | 0.18 | 0.57 | 0.22 | 0.44 | 0.61 | 0.36 | 0.35 | 0.46 | 0.47 | 0.92 | | Current ratio | | | | | 4.35 | 1.39 | 3.21 | 2.96 | 2.67 | 2.37 | 2.00 | 2.01 | 1.82 | 2.49 | ## As-reported value updates 12 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period. Ledger: /company/MYGN/revisions/ ## Quarterly Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-07-31. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000899923.json. Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived. | Quarter | End date | Revenue | Net income | Diluted EPS | Method | | --- | --- | ---: | ---: | ---: | --- | | 2022-Q3 | 2022-09-30 | | | -0.43 | reported discrete quarter | | 2023-Q1 | 2023-03-31 | | | -0.67 | reported discrete quarter | | 2023-Q2 | 2023-06-30 | | | -1.42 | reported discrete quarter | | 2023-Q3 | 2023-06-30 | | -116,100,000 | | reported discrete quarter | | 2023-Q3 | 2023-09-30 | 191,900,000 | | -0.75 | reported discrete quarter | | 2023-Q4 | 2023-12-31 | 196,600,000 | -31,200,000 | | derived Q4 = FY annual - nine-month YTD | | 2024-Q1 | 2024-03-31 | 202,200,000 | -26,000,000 | -0.29 | reported discrete quarter | | 2024-Q2 | 2024-03-31 | | -26,000,000 | | reported discrete quarter | | 2024-Q2 | 2024-06-30 | 211,500,000 | | -0.41 | reported discrete quarter | | 2024-Q3 | 2024-06-30 | | -36,700,000 | | reported discrete quarter | | 2024-Q3 | 2024-09-30 | 213,300,000 | | -0.24 | reported discrete quarter | | 2024-Q4 | 2024-12-31 | 210,600,000 | -42,500,000 | | derived Q4 = FY annual - nine-month YTD | | 2025-Q1 | 2025-03-31 | 195,900,000 | -100,000 | 0.00 | reported discrete quarter | | 2025-Q2 | 2025-03-31 | | -100,000 | | reported discrete quarter | | 2025-Q2 | 2025-06-30 | 213,100,000 | | -3.57 | reported discrete quarter | | 2025-Q3 | 2025-06-30 | | -330,500,000 | | reported discrete quarter | | 2025-Q3 | 2025-09-30 | 205,700,000 | | -0.29 | reported discrete quarter | | 2025-Q4 | 2025-12-31 | 209,800,000 | -7,900,000 | | derived Q4 = FY annual - nine-month YTD | | 2026-Q1 | 2026-03-31 | 200,400,000 | -34,100,000 | -0.36 | reported discrete quarter | | 2026-Q2 | 2026-03-31 | | -34,100,000 | | reported discrete quarter | | 2026-Q2 | 2026-06-30 | 190,700,000 | | -0.46 | reported discrete quarter | ## Filed narrative (10-K & 10-Q) ## Business Verbatim Item 1 Business section from MYGN's latest 10-K: [/company/MYGN/business/](/company/MYGN/business/). ## Risk Factors Verbatim Item 1A Risk Factors from MYGN's latest 10-K: [/company/MYGN/risk-factors/](/company/MYGN/risk-factors/). ## Latest quarter (10-Q) Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/899923/000089992326000072/mygn-20260630.htm Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture. Confidence: high Filing date: 2026-07-31 Report date: 2026-06-30 Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the related notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and related notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2025 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on February 24, 2026. “We,” “us,” “our,” “Myriad” and the “Company” as used in this Quarterly Report on Form 10‑Q refer to Myriad Genetics, Inc., a Delaware corporation, and its subsidiaries. Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, MyChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Foresight Universal Plus, Precise Tumor, Precise Oncology Solutions, Precise Liquid, Precise MRD, FirstGene, SneakPeek, SneakPeek Early Gender DNA Test, SneakPeek Snap, Urosuite, Mygenehistory, Health.Illuminated., RiskScore, Prolaris, Prolaris + AI, and GeneSight are registered trademarks or trademarks of Myriad. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report on Form 10-Q may appear without the ®, ™ or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. Cautionary Statement Regarding Forward-Looking Statements The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10‑Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes,” “seek,” “could,” “continue,” “likely,” “will,” “strategy,” and “goal” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. All forward-looking statements are management’s present expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: •the risk that sales and profit margins of our existing tests may decline; •the risk that we may not be able to operate our business on a profitable basis; •risks related to our ability to achieve certain revenue growth targets and generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests to be profitable; •risks related to recent changes in our senior management team and the successful implementation of our strategic plan; •risks related to changes in governmental or private insurers’ coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; •risks related to increased competition and the development of new competing tests; •the risk that we may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; •the risk that we may not successfully develop new markets or channels for our tests; •the risk that licenses to the technology underlying our tests and any future tests are terminated or cannot be maintained on satisfactory terms; •risks related to delays or other problems with operating our laboratory testing facilities; •risks related to public concern over genetic testing in general or our tests in particular; •risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; •risks related to our ability to obtain new corporate partnerships and collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; •risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license, acquire, or develop; •the risk that we are not able to secure additional financing to fund our business, if needed, in a timely manner or on favorable terms, if at all; 20 Table of Contents •risks related to our projections or estimates about the potential market opportunity for our current and future products; •the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; •the risk of patent-infringement claims or challenges to the validity of our patents; •risks related to changes in intellectual property laws covering our tests, or patents or enforcement, in the United States and foreign countries; •risks related to security breaches, loss of data and other disruptions, including from cyberattacks and other cybersecurity incidents; •risks of new, changing and competitive technologies in the United States and internationally, and that we may not be able to keep pace with the rapid technology changes in our industry, or properly leverage new technologies to achieve or sustain competitive advantages in our products; •the risk that we may be unable to comply with financial or operating covenants under our credit or lending agreements; •the risk that we may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting; •risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of our insurance coverage limits and scope of insurance coverage with respect thereto; and •other factors discussed under the heading "Risk Factors" contained in Part I, Item 1A of our Annual Report on Form 10-K filed with the SEC on February 24, 2026, as updated under the heading "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q, and subsequent filings we make with the SEC. In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q, or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law. All forward-looking statements in this Quarterly Report on Form 10-Q attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. General Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. We believe there are significant growth opportunities in addressing the pressing healthcare needs of patient populations through innovative molecular diagnostic testing and precision medicine solutions and services. Our long-term growth strategy is built on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine. Our strategy also leverages investments in science and innovation, technology-enabled operations, an enhanced customer experience, strong commercial execution, and scalable operations. Our strategic intent is to accelerate profitable growth by focusing on (i) providing a comprehensive testing menu for the Cancer Care Continuum market with a priority for high growth applications; (ii) growing our Prenatal Health and Mental Health revenues at or above market growth; and (iii) delivering sustained profitable growth through financial and operational discipline and leveraging our operating model. Under this strategy, we plan to leverage our strong scientific foundation, deep clinical partnerships, and technology-enabled capabilities to expand adoption of our testing portfolio and integrate our precision medicine solutions more deeply into clinical workflows across the Cancer Care Continuum, Prenatal Health, and Mental Health. We are committed to making molecular testing accessible and actionable for patients and providers while driving long-term growth and profitability. 21 Table of Contents Business Updates Our recent significant business updates include the following: •In July 2026, we engaged a leading professional services firm to support initiatives intended to increase efficiency and scalability to accelerate profitable growth. •In July 2026, we announced results from a new large-scale meta-analysis demonstrating the strong prognostic performance of our Prolaris biopsy test in localized prostate cancer. •In June 2026, we announced the appointment of Raj Jampa as our new Chief Technology Officer, effective June 1, 2026. •In June 2026, we announced expanded availability of Precise MRD for colorectal, renal, and breast cancers, supported by new published data further supporting the assay's performance and clinical utility. •In May 2026, we launched Prolaris + AI, the first prostate cancer test to combine genomics and digital pathology artificial intelligence, or AI, which we believe further enhances personalized treatment insights for prostate cancer patients and their physicians. •In April 2026, we announced the presentation of six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) 2026 Annual Meeting, highlighting continued clinical evidence supporting our oncology portfolio. Results of Operations for the Three Months Ended June 30, 2026 and 2025 The results of operations for the three months ended June 30, 2026 and 2025 are discussed below. Revenue The following table summarizes year-over-year revenue changes in our core product categories: [[GREPCENT_TABLE]] [["","Three months ended June 30,","","","","% of Total Revenue"],["(in millions)","2026","","","2025","","Change","","2026","","","2025"],["Cancer Care Continuum","$","114.1","","","","$","127.7","","","$","(13.6)","","","60%","","","60%"],["Prenatal Health","39.8","","","","47.6","","","(7.8)","","","21%","","","22%"],["Mental Health","36.8","","","","37.8","","","(1.0)","","","19%","","","18%"],["Total revenue","$","190.7","","","","$","213.1","","","$","(22.4)","","","100%","","","100%"]] [[/GREPCENT_TABLE]] The following table summarizes volume changes in our core product categories: [Excerpt truncated for page length; source filing is linked above.] ## Latest 10-K MD&A (excerpt) Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/mygn-20251231.htm Complete FY 2025 MD&A: /company/MYGN/mda/fy2025/ Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture. Confidence: high Filing date: 2026-02-24 Report date: 2025-12-31 Item 7.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes thereto included elsewhere in this Annual Report on Form 10-K. This Management’s Discussion and Analysis of Financial Condition and Results of Operations provides an overview of our business and 2025 financial highlights and describes principal factors affecting the results of our operations, financial condition and liquidity, as well as our critical accounting estimates that require significant judgment and thus have the most significant potential impact on our Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K. The discussion and analysis below includes year-to-year comparisons between the year ended December 31, 2025 and the year ended December 31, 2024. Discussions of comparisons between the year ended December 31, 2024 and the year ended December 31, 2023 that are not included in this Annual Report on Form 10-K can be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 of Part II of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025. Unless otherwise noted, all of the financial information in this Annual Report on Form 10-K is consolidated financial information of the Company. Overview Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care. We believe that engaging with providers and patients throughout their consumer and patient journey will better enable us to execute our strategies and fulfill our mission. We believe there are significant growth opportunities in addressing the pressing healthcare needs of patient populations through innovative molecular diagnostic testing and precision medicine solutions and services. Our long-term growth strategy is built on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine. Our strategy also leverages investments in science and innovation, technology-enabled operations, an enhanced customer experience, strong commercial execution, and scalable operations. Our strategic intent is to accelerate profitable growth by focusing on (i) providing a comprehensive testing menu for the Cancer Care Continuum (CCC) market with a priority for high growth applications; (ii) growing our Prenatal Health and Mental Health revenues at or above market growth; and (iii) delivering sustained profitable growth through financial and operational discipline and leveraging our operating model. Under this strategy, we plan to leverage our strong scientific foundation, deep clinical partnerships, and technology-enabled capabilities to expand adoption of our testing portfolio and integrate our precision medicine solutions more deeply into clinical workflows across the Cancer Care Continuum, Prenatal Health, and Mental Health. Cancer remains one of the most prevalent diseases, with more than two million new cases diagnosed, and more than eighteen million survivors, in the United States in 2025. Myriad is a pioneer in DNA based cancer diagnostic testing, and a trusted leader in hereditary cancer testing across eleven of the most commonly occurring cancer types including breast, ovarian, colorectal, prostate, lung and skin. We are also a leader in cancer therapy selection with our Homologous Recombination Deficiency (HRD) test and are planning to strengthen our portfolio of comprehensive genomic profiling tests through product development and partnerships. We see molecular residual disease (MRD) testing as a significant opportunity for patient impact and revenue growth. We believe Myriad’s ultra-sensitive Precise MRD offering, combined with our growing portfolio of other relevant diagnostic tests that are a common part of cancer care and, our commercial leadership in serving community medicine, will enable us to establish and grow a meaningful MRD business over the coming years. 64 Table of Contents As part of our Cancer Care Continuum strategy, we also plan to expand the number of biopharma partners we serve with services including biomarker identification and validation, companion diagnostic test development and regulatory registration, as well as companion diagnostic test commercialization. Complementing our own capabilities with partnerships that enable us to bring compelling solutions to market more quickly is an important part of our strategy. In early 2025, we entered into a strategic collaboration with PATHOMIQ, Inc. pursuant to which we obtained exclusive U.S. licensing rights to PATHOMIQ’s AI-enabled diagnostic platform, PATHOMIQ_PRAD, to enhance our oncology portfolio and offer AI-driven prognostic and predictive solutions for prostate cancer care. In September 2025, we entered into a strategic collaboration with SOPHiA GENETICS S.A. to develop a global liquid biopsy companion diagnostic solution. We continue to invest in clinical evidence development to support the growth of our existing products and launch of new products, such as FirstGene and Precise MRD. We believe these investments in product innovation position us to expand our addressable markets and differentiate our portfolio of testing solutions. We plan to continue to develop and enhance our products and services to support growth, improve patient and provider experience, and reach more patients of all backgrounds. In addition, by investing in technology-enabled commercial tools, advanced automation, and standardized processes and technology, we believe we will be able to reduce complexity and cost, while enhancing our ability to scale and grow. In 2025, we completed the transition of our laboratory operations to our next-generation laboratory facilities, which are designed to enhance automation, reduce turnaround time, and improve cost efficiency across our testing portfolio. We believe these improvements, combined with our ongoing operational initiatives, position us to achieve greater scalability and reduce operating expenses as a percentage of revenue over time. We are committed to making molecular testing accessible and actionable for patients and providers while driving long-term growth and profitability. Our consolidated revenues consist primarily of sales of genetic tests through our wholly-owned subsidiaries. During the year ended December 31, 2025, we reported total revenue of $824.5 million, a net loss of $365.9 million, and basic and diluted loss per share of $3.95. 65 Table of Contents Business Updates and Financial Highlights During the year ended December 31, 2025, our significant business updates and financial highlights include the following: •Revenue decreased 2% year-over-year to $824.5 million, which was driven in part by the discontinuation of coverage by UnitedHealthcare of GeneSight and the divestiture of the European EndoPredict business in the prior year. Volumes increased approximately 1% from the prior year. •In November 2025, we expanded the MyRisk Hereditary Cancer Test to include 63 genes across 11+ cancer types, further strengthening our comprehensive hereditary cancer offering. •In October 2025, we announced the addition of two genes, F8 and FXN, to the Foresight Carrier Screen Universal Plus Panel. •In September 2025, we announced a strategic collaboration with SOPHiA Genetics, Inc. to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. •In September 2025, we announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual. •In July 2025, we closed a $125 million secured term debt facility with OrbiMed, a leading global healthcare investment firm. This facility includes an option to borrow up to an additional $75 million. •In July 2025, we earned the Great Place to Work Certification for the third consecutive year. •In June 2025, we launched early access to FirstGene Multiple Prenatal Screen, a prenatal genetic risk assessment screen that combines several testing modalities into a single assay, in a large, multi-site study, called CONNECTOR. •New clinical data supporting the performance and potential clinical utility of our Precise MRD test was presented at major scientific conferences, including the American Association for Cancer Research and the American Society of Clinical Oncology Annual Meeting. These presentations include data from a prospective pan-cancer study conducted by our partner, the National Cancer Center Hospital East in Japan. •Effective April 30, 2025, Samraat Raha was appointed President and Chief Executive Officer and Mark Verratti was appointed Chief Operating Officer; Brian Donnelly was appointed Chief Commercial Officer effective May 1, 2025; and Benjamin R. Wheeler was appointed Chief Financial Officer effective August 16, 2025. 66 Table of Contents Seasonality The Company has historically experienced some seasonality in its business, including due to factors such as the timing of deductibles resetting or being met. While the Company continues to experience periodic fluctuations in quarterly revenues, these variations are increasingly influenced by other factors such as the timing of customer activity, reimbursement dynamics, and broader market conditions. Additionally, we believe operating results for the twelve months ended December 31, 2025 may not necessarily be indicative of results to be expected for any other year. Components of Consolidated Operations Revenue. Our tests are designed to analyze genes and their expression levels to assess an individual’s risk for developing disease, determine a patient’s likelihood of responding to a particular drug, assess a patient’s risk of disease progression, identify factors which could lead to serious conditions in pregnancy, or provide other prenatal insights. Revenue is recognized when the test results have been released to the healthcare provider and/or patient. Expenses. Personnel-related costs for each category of costs and expenses include salaries, bonuses, employee benefit costs, employer payroll taxes, and stock-based compensation. Cost of Revenue. Cost of revenue consists primarily of costs related to laboratory supplies, personnel-related costs, and overhead costs. General and Administrative Expense. General and administrative expenses include executive management, billing and collections, finance and accounting, information technology, legal, and human resources. These expenses include personnel-related costs and third-party costs for items such as audit fees, legal expenses, consulting costs, and information technology services. Sales and Marketing Expense. Sales and marketing expenses include costs associated with growing our business and providing cus [Excerpt truncated for page length; the complete text is on the linked full-MD&A page.] Read the full FY 2025 MD&A: /company/MYGN/mda/fy2025/ All MD&A years: /company/MYGN/mda/ ## MD&A history Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page. - [FY 2024 MD&A](/company/MYGN/mda/fy2024/): filed 2025-02-28; accession 0000899923-25-000019 (https://www.sec.gov/Archives/edgar/data/899923/000089992325000019/mygn-20241231.htm) - [FY 2023 MD&A](/company/MYGN/mda/fy2023/): filed 2024-02-28; accession 0000899923-24-000018 (https://www.sec.gov/Archives/edgar/data/899923/000089992324000018/mygn-20231231.htm) - [FY 2022 MD&A](/company/MYGN/mda/fy2022/): filed 2023-03-01; accession 0000899923-23-000011 (https://www.sec.gov/Archives/edgar/data/899923/000089992323000011/mygn-20221231.htm) - [FY 2021 MD&A](/company/MYGN/mda/fy2021/): filed 2022-02-25; accession 0000899923-22-000033 (https://www.sec.gov/Archives/edgar/data/899923/000089992322000033/mygn-20211231.htm) ## FDA-approved drug applications Applications listed under this company's exact-matched sponsor name. Approved applications only. No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule. Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers. This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent. ## Macro cross-references Indicators mapped to this company's SIC classification (industry 2835 In Vitro & In Vivo Diagnostic Substances) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim. - [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index - [TCU](/indicator/TCU/): Capacity Utilization: Total Index - [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities - [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product - [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity - [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate - [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private - [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/). All macro indicators: /indicators/ ## For LLMs & downloads Markdown twin: /company/MYGN.md · JSON record: /company/MYGN.json · verified financials: /company/MYGN/financials.json / /company/MYGN/financials.csv · machine TOC for the whole site: /llms.txt